Lircetam 500 Tablet contains Levetiracetam 500 mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and preventing seizure propagation. Lircetam 500 is typically prescribed as adjunctive therapy but may also be used as monotherapy depending on clinical judgment. The tablet should be administered orally, with or without food, and dosage individualized based on patient response and tolerability. Common adverse effects include somnolence, dizziness, headache, and fatigue, while serious reactions such as behavioral changes, mood alterations, or hypersensitivity require prompt medical attention. Caution is advised in patients with renal impairment, necessitating dose adjustment. Lircetam 500 is contraindicated in individuals with known hypersensitivity to Levetiracetam or any excipients. Regular monitoring of seizure control and side effects is recommended to optimize therapeutic outcomes. Patients should be advised not to discontinue therapy abruptly to avoid increased seizure risk. Lircetam 500 Tablet offers a well-tolerated and effective option for seizure management, improving quality of life in patients with epilepsy.